Advanced Search

 

Study ID Status Title Patient Level Data
EGF110557 Completed An Open-Label, Two-Part, Single Sequence Study to Examine the Effects of Lapatinib on the Pharmacokinetics of Orally Administered Digoxin in Subjects with Metastatic ErbB2 Positive Breast Cancer
EGF110656 Active, not recruiting A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma treated with Capecitabine plus Oxaliplatin with or without Lapatinib
EGF19060 Completed An Open Label, Phase 1b Rollover Study to Assess the Long-Term Safety Profile of Lapatinib (GW572016) in Cancer Patients.
EGF20001 Completed A parallel-arm, multi-center, open-label randomized phase II study of orally administered GW572016 as single-agentsecond-line treatment of patients with locally advanced or metastatic renal cell carcinoma
EGF20003 Completed A single-arm, multi-centre, open-label phase II study of orally administered GW572016 as single-agent second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract
EGF20004 Completed An Open-Label, Multicenter, Phase II Study of Oral Lapatinib (GW572016) as Single Agent, Second-Line Therapy in Subjects with Metastatic Colorectal Cancer Who Have Progressed on First-Line Therapy with 5-Fluorouracil in Combination with Irinotecan or Oxaliplatin
EGF20008 Completed An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects with Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens
EGF20009 Completed A Phase II, Open-Label, Randomized, Parallel-Group Multicenter Trial Comparing Two Schedules of GW572016 as First-Line Monotherapy in Patients with Advanced or Metastatic Breast Cancer
EGF20014 Terminated A Phase 2 Multicenter Trial Comparing Two Schedules of GW572016 as First or Second Line Monotherapy in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer with either Bronchioloalveolar Carcinoma or No Smoking History
EGF30001 Completed A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 in Combination with Paclitaxel in Subjects Previously Untreated or Advanced or Metastatic Breast Cancer
EGF30008 Active, Not Recruiting A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing GW572016 and Letrozole versus Letrozole in Subjects with Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer
EPI40105 Completed A post-marketing surveillance study of subject-reported adverse events rates for Malarone (atovaquone and proguanil), mefloquine and chloroquine/proguanil, when used for prophylaxis for travel up to 28 days maximum
FAP10001 Completed Dose proportionality of fluticasone propionate from HFA inhalers and effect of propellant on FP pharmacokinetics Study Listed on ClinicalStudyDataRequest.com
FAP10006 Completed A Randomized, Open-Label, 2-Way Crossover, Repeat-Dose Study in Pediatric Subjects with Asthma, Age 4-11 Years, to Compare Systemic Exposure of Fluticasone Propionate 2x44mcg Following Administration by Metered-Dose Inhalers Containing Hydrofluoroalkane or Chlorofluorocarbon Propellants Study Listed on ClinicalStudyDataRequest.com
FAP19052 Completed Pharmacodynamics of the 88mcg BID dose of the Hydrofluoroalkane propellant formulation of inhaled Fluticasone Propionate following Administration via the Metered-dose Inhaler in Pediatric Subjects 4 to 11 years of age with Asthma Study Listed on ClinicalStudyDataRequest.com
FAP19058 Completed Systemic exposure of the fluticasone propionate from the hydrofluoroalkane propellant formulation via the metered-dose inhaler with and without a spacer in pediatric subjects 4 to 11 years of age with asthma. Study Listed on ClinicalStudyDataRequest.com
FAP30007 Completed A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID, and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Inhaled Corticosteroid Therapy Study Listed on ClinicalStudyDataRequest.com
FAP30008 Completed A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 12-Week Trial of Inhaled Fluticasone Propionate 88mcg BID, 220mcg BID, and 440mcg BID versus Placebo in Propellant GR106642X in Adolescent and Adult Subjects with Asthma who are Maintained on Bronchodilator Therapy Study Listed on ClinicalStudyDataRequest.com
FAP30010 Completed A Randomized, Double-Blind, Paralled-Group, Placebo-Controlled 12 Week Trial of Inhaled Fluticasone Propionate 88mcg Twice Daily versus Placebo in Propellant GR106642X in Pediatric Subjects 4 to 11 years of age with Asthma Study Listed on ClinicalStudyDataRequest.com
FAS10002 Completed A multiple-dose, open-label, 2-way crossover study in pediatric subjects with asthma aged 1 to < 4 years to compare the systemic exposure of fluticasone propionate 88mcg administered via the hydrofluoroalkane metered-dose inhaler using the valved holding chambers, Aerochamber Plus™ and Babyhaler™, with face-masks Study Listed on ClinicalStudyDataRequest.com
FAS106533 Completed PD of Hydrofluoroalkane propellant of inhaled fluticasone propionate following administration in pediatric subjects 6-12 months of age with asthma Study Listed on ClinicalStudyDataRequest.com
FAS30007 Completed A multicentre, randomised, double-blind, parallel group placebo-controlled study to determine the efficacy and safety of fluticasone propionate 200mcg/day delivered via the Babyhaler in paediatric subjects aged 12 to 47 months with recurrent/persistent asthma like symptoms. Study Listed on ClinicalStudyDataRequest.com
FAS30009 Completed A multicentre, randomised, parallel-group open label study to assess the long term safety of fluticasone propionate 100mcg bd via the MDI and babyhaler spacer device, compared with sodium cromoglycate 5mg QDS in children aged 12-47months with documented evidence of recurrent/persistent asthma-like symptoms. Study Listed on ClinicalStudyDataRequest.com
FAS30030 Completed A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Safety and Efficacy Study of Fluticasone Propionate 88mcg BID Versus Placebo BID delivered via HFA MDI and a valved holding chamber with facemask in Pediatric Subjects with Asthma age 12 months to 47 months. Study Listed on ClinicalStudyDataRequest.com
FAS40008 Completed An interventional three year study for asthma control - In what way and in what kind of population is it possible to get asthmatic patients free from symptoms, keep the patients in work, restore a normal lung function, diminish hyperreactivity and normalise quality of life? Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.